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Background
Abnormal interactions between red blood cells, leukocytes and endothelial cells play a critical
role in the occurrence of the painful vaso-occlusive crises associated with sickle cell disease. We
investigated the interaction between circulating leukocytes and red blood cells which could
lead to aggregate formation, enhancing the incidence of vaso-occlusive crises.
Design and Methods
Blood samples from patients with sickle cell disease (n=25) and healthy subjects (n=5) were
analyzed by imaging and classical flow cytometry after density gradient separation. The iden-
tity of the cells in the peripheral blood mononuclear cell layer was determined using antibodies
directed specifically against white (anti-CD45) or red (anti-glycophorin A) blood cells.
Results
Aggregates between red blood cells and peripheral blood mononuclear cells were visualized in
whole blood from patients with sickle cell disease. The aggregation rate was 10-fold higher in
these patients than in control subjects. Both mature red blood cells and reticulocytes were
involved in these aggregates through their interaction with mononuclear cells, mainly with
monocytes. The size of the aggregates was variable, with one mononuclear cell binding to one,
two or several red blood cells. Erythroid Lu/basal cell adhesion molecule and α4β1 integrin were
involved in aggregate formation. The aggregation rate was lower in patients treated with
hydroxycarbamide than in untreated patients.
Conclusions
Our study gives visual evidence of the existence of circulating red blood cell-peripheral blood
mononuclear cell aggregates in patients with sickle cell disease and shows that these aggregates
are decreased during hydroxycarbamide treatment. Our results strongly suggest that erythroid
Lu/basal cell adhesion molecule proteins are implicated in these aggregates through their inter-
action with α4β1 integrin on peripheral blood mononuclear cells.
Key words: α4β1, Lu/BCAM, sickle cell disease, aggregates.
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Introduction
Sickle cell disease is a monogenic red blood cell disorder
resulting from a single amino acid substitution in the
hemoglobin (Hb) β-chain. This abnormal hemoglobin,
named HbS, polymerizes under deoxygenated conditions
leading to the formation of less deformable sickle red
blood cells (SS RBC). Vaso-occlusive crises are the main
acute complication of sickle cell disease and are the conse-
quence of obstruction of blood microvessels by SS RBC.1
Indeed, in addition to their propensity to sickle, SS RBC
can also adhere to vascular endothelium contributing to
vaso-occlusive crises.2,3 Several studies, using in vitro and ex
vivo models, have identified multiple adhesion proteins
involved in SS RBC adhesion to endothelium. One of the
most characterized RBC adhesion molecules is α4β1 inte-
grin (or very late antigen-4, VLA-4), expressed on reticulo-
cytes, which binds to vascular cell adhesion molecule-1
(VCAM-1), thrombospondin and fibronectin.4-7
Lutheran/basal cell adhesion molecule (Lu/BCAM) pro-
teins, the unique receptors for laminin in normal (AA) and
SS RBC,8-10 could be involved in vaso-occlusive crises.
Unlike AA RBC, SS RBC adhere to laminin and resist high
shear stress forces.8,11 Lu/BCAM-mediated SS RBC adhe-
sion to laminin is stimulated by the physiological stress
mediator epinephrine through the β2-adrenergic receptor
and protein kinase A signaling pathway.12,13 Lu/BCAM pro-
teins are also constitutively expressed on the endothelial
cell surface and interact with α4β1 integrin expressed on
young SS RBC, which may contribute to the abnormal
adhesion of these RBC to resting endothelium.14
In addition to SS RBC, clinical observations suggested a
role for leukocytes in the pathophysiological scheme of
sickle cell disease.15-18 High leukocyte counts are associated
with sickle cell disease-related morbidity and mortality19-23
and experimental studies suggested that leukocytes con-
tribute to the vaso-occlusive process. Leukocytes from
patients with sickle cell disease adhere abnormally to vas-
cular endothelium in vitro24 and play a critical role in the
vaso-occlusive phase of sickle cell retinopathy.25 Infusion
of epinephrine-activated human SS RBC into nude mice
induces vaso-occlusion associated with adhesion of
murine leukocytes to vascular endothelium.26 Further -
more, sickle cell disease mice deficient in endothelial P and
E-selectins, important mediators of leukocyte recruitment
to the vessel wall, are protected from vaso-occlusion.27
Beside their adhesion to the vessel wall through interac-
tions with endothelial and extracellular matrix proteins,
leukocytes can also interact with circulating SS RBC lead-
ing to the formation of aggregates and enhancing the inci-
dence of vaso-occlusive crises. SS RBC adhere to polymor-
phonuclear neutrophils in vitro28 and are captured by adher-
ent leukocytes, as shown by intravital microscopy in mice
expressing human HbS27 as well as in a flow model of
vaso-occlusion in vitro.29 Brittain et al. showed interactions
between reticulocytes and monocytes in whole blood
samples and in adhesion assays in vitro.30 These interac-
tions are mediated by α4β1 integrin, expressed on both cell
types, via a bridge of soluble fibronectin.30 Furthermore, in
vitro experiments suggested that SS RBC bind to peripheral
blood mononuclear cells (PBMC) via erythroid LW/ICAM-
4 and CD44 receptors, and induce their adhesion to
endothelium.31
In this study we used innovative imaging flow cytome-
try technique to visualize directly RBC-PBMC aggregates
in a layer of enriched PBMC obtained by density gradient
separation of SS whole blood. We studied the nature of
these aggregates, the protein interactions facilitating their
formation and the effects of hydroxycarbamide treatment,
given that this drug is know to reduce the frequency of
vaso-occlusive crises.32
Design and Methods 
Patients
Homozygous sickle cell disease patients (SS) at least 18 years
old, able to give their informed consent and consulting our Adult
Sickle-Cell Referral Center were eligible for inclusion in this study
which was approved by the local ethics committee (Comité de
Protection des Personnes) and was conducted in accordance with the
provisions of the Declaration of Helsinki, and local laws and regu-
lations. Experiments were performed with freshly drawn heparin-
anticoagulated venous blood from healthy adult donors or adult
SS patients at steady-state, treated or not with hydroxycarbamide.
A patient was defined as having steady state disease when at least
1 month had passed since an acute clinical event and at least 3
months since a blood transfusion. We selected 17 SS patients
untreated with hydroxycarbamide (mean age: 34 years, SD: 8
years; male to female sex ratio: 12/5) and eight patients on stable
hydroxycarbamide therapy (20 mg/kg/day for >6 months) (mean
age: 37 years, SD: 10 years; male to female sex ratio: 4/4). These
two groups were studied independently. Blood samples from five
healthy adult donors (AA) were used as control samples.
Preparation of the peripheral blood mononuclear 
cell layer
Venous blood was collected from the antecubital vein into lithi-
um heparin (17 U.l/mL) tubes (Becton Dickinson Vacutainer,
Plymounth, UK). PBMC were separated from whole blood using
Ficoll-Histopaque-1077 (Sigma-Aldrich, Saint Louis, MO, USA)
density gradient separation and the isolated cells were washed
once with phosphate-buffered saline containing calcium (1 mM)
and magnesium (1 mM).
Labeling and blocking experiments
Cells were incubated with mouse monoclonal anti-human
CD45-fluorescein isothiocyanate (FITC) and glycophorin A (GPA)-
phycoerythrin (PE) or GPA-allophycocycanin (APC) conjugated
antibodies (Becton Dickinson Biosciences, San Jose, CA, USA) for
60 min and washed with phosphate-buffered saline before flow
cytometry or imaging flow cytometry analysis. For triple staining
experiments, monoclonal anti-human CD71-APC conjugated anti-
body (Becton Dickinson Biosciences) was added. Indirect labeling
was used for Lu/BCAM: cells were incubated with a goat poly-
clonal antibody anti-human Lu/BCAM (R&D systems,
Minneapolis, MN, USA) for 90 min, washed with phosphate-
buffered saline, then incubated with a swine anti-goat-PE second-
ary antibody (Beckman Coulter, Fullerton, CA, USA) together
with anti-CD45-FITC and anti-GPA-APC antibodies.
For blocking experiments, the reagents were added prior to
labeling. Cells from the mononuclear enriched layer were incubat-
ed for 30 min with 40 μg/mL recombinant human VCAM-1-Fc
chimera (R&D systems, Minneapolis, MN, USA) or 40 μg/mL
mouse monoclonal anti-human CD29 antibody (Becton
Dickinson Biosciences).
Flow cytometry analysis
Acquisition and analysis were performed using a BD FACS
Canto II flow cytometer (Becton Dickinson Biosciences) via BD
V. Chaar et al.
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FACSDiva software (v6.1.2). A total of 5¥105 events were collected
for each experiment. Monocytes and lymphocytes of the PBMC
layer were identified and gated by forward and side scatter.
PBMC, RBC and aggregates were quantified as the percentage of
events that stained positive for CD45 (% CD45+), GPA (% GPA+)
and both antigens (% CD45+ GPA+), respectively. The percentage
of PBMC involved in aggregates among total CD45+ events (%
PBMC in aggregates) was determined for each subject according to
the following formula:
% PBMC in aggregates = {% CD45+ GPA+ / (% CD45+ + %
CD45+ GPA+)} x 100
Imaging flow cytometry analysis
Acquisition and analysis were performed using the
ImageStream system (Amnis Corporation, Seattle, WA, USA) and
the ImageStream Data Exploration and Analysis Software (IDEAS;
Amnis). This software enables quantitative characterization of sin-
gle cells or aggregates within a population by assessing a combina-
tion of morphology and fluorescence patterns. The ImageStream
system is equipped with three laser lines 405, 488 and 658 nm.
Samples were prepared as described above. Spectral compensa-
tion was performed as described by Ortyn et al.33 Cell populations
were identified by gating on cells expressing surface markers and
confirmed by visual inspection of the fluorescence pattern.
Statistical analyses
The Mann-Whitney test was used to determine: (i) differences
in RBC and PBMC proportions between untreated SS patients and
AA subjects; (ii) differences in the percentage of PBMC in aggre-
gates between untreated SS patients and AA subjects and between
untreated and hydroxycarbamide-treated SS patients. Blocking
experiments were analyzed using Wilcoxon's matched-pairs test.
P values less than 0.05 were considered statistically significant.
Results
Abnormal co-selection of red blood cells and peripheral
blood mononuclear cells in patients with sickle cell
disease
PBMC were isolated from whole blood samples by
Ficoll-Histopaque gradient separation. Cells from the
PBMC layer were analyzed by flow cytometry using
FITC-conjugated anti-CD45 and PE-conjugated anti-GPA
antibodies specific for white blood cells and RBC, respec-
tively. As illustrated in Figure 1A, an abnormally high per-
centage of RBC, determined by the percentage of GPA-PE
events, was observed in the PBMC layer of SS patients
(typical result, n=17). This percentage was highly variable
among SS patients and the median percentage was signif-
icantly higher for SS patients than for AA controls (26.4
versus 3.7, P=0.0013) (Figure 1B).
High rate of red blood cell and peripheral blood
mononuclear cell aggregates in patients 
with sickle cell disease
A high number of events double-positive for both
CD45-FITC and GPA-PE were detected in all SS patients in
contrast to AA subjects (Figure 2A, typical result, n=17).
We postulated that these events could represent aggre-
gates between RBC and PBMC. To test this hypothesis,
we used imaging flow cytometry. We analyzed the PBMC
layer of one SS patient and one AA subject after CD45-
FITC and GPA-PE staining. Images obtained from the SS
patient showed that the double-stained events did indeed
correspond to PBMC-RBC aggregates (Figure 2B). Three
populations of PBMC-RBC aggregates could be distin-
guished according to the GPA-PE intensity, all of which
involved one PBMC which interacted with either one,
two, or more than two RBC. A fourth population involv-
ing PBMC and small RBC-derived microparticles was also
observed. The rare double-stained events observed in AA
subjects were mainly PBMC interacting with RBC-derived
microparticles (Figure 2B, AA subject).
Based on the imaging flow cytometry findings, gating of
double-stained events was improved in classical flow
cytometry experiments, excluding the aggregates between
PBMC and RBC-derived microparticles. As the RBC per-
centage in the PBMC layer was variable among SS
patients, the aggregation rate was determined by calculat-
ing the percentage of PBMC involved in the aggregates.
The median of this percentage was 10-fold higher in SS
patients than in healthy controls (2.11 versus 0.2,
P=0.0048) (Figure 2C).
Aggregates include reticulocytes, mature red blood
cells and monocytes
To determine the maturity of the SS RBC population
involved in aggregation, cells were double stained with
anti-GPA and anti-CD71 antibody which recognizes the
transferrin receptor, specific to reticulocytes among the
RBC population. First, the RBC population of the PBMC
layer (Figure 3A, typical result, left panel) was analyzed
and showed the presence of both mature RBC and reticu-
locytes (Figure 3A, middle panel). The percentage of retic-
ulocytes in this layer differed among the seven tested
patients but was always higher than that in whole blood,
indicating a preferential selection of reticulocytes during
the density separation. When aggregates were gated, they
showed CD71-positive and CD71-negative populations,
indicating that both young and mature RBC were involved
in aggregation with PBMC (Figure 3A, right panel). The
median of CD71-positive RBC in aggregates was 58.4%
(n=7).
The percentages of lymphocytes and monocytes in the
PBMC population and in the aggregates of nine patients
were determined using forward and side scatters (Figure
3B, typical result). In the PBMC population, the majority
of the cells were lymphocytes (median: 97.8%). Despite
the small percentage of monocytes in the PBMC popula-
tion (median: 2.2%), they represented the majority of
PBMC involved in aggregation (median: 60.7%), indicat-
ing that RBC preferentially interacted with monocytes
within the aggregates (Figure 3C).
α4β1 integrin and erythroid Lu/basal cell adhesion 
molecule are involved in aggregate formation
To identify the adhesion proteins involved in aggregate
formation, inhibition assays were performed with specific
ligands of α4β1 integrin, which is expressed on all PBMC
and a population of reticulocytes. When soluble VCAM-1-
Fc was added, the percentage of aggregates was signifi-
cantly reduced (median: 2.4% versus 3.7%, n=6, P=0.03)
(Figure 4A). Incubation with anti-β1 blocking antibody also
inhibited aggregation in six other samples (median: 0.98%
versus 1.45%, P=0.03) (Figure 4B), indicating that α4β1 inte-
grin was involved in the formation of the aggregates. 
As Lu/BCAM glycoproteins are known to interact with
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α4β1 integrin,14 their implication in aggregation was inves-
tigated. Lu/BCAM antigens vary greatly in strength among
individuals and exhibit heterogeneity between individual
RBC within a person. This accounts for the mixed field
agglutination patterns showing clumps of agglutinated
cells in the presence of free cells.34 The distribution of
Lu/BCAM antigens among the PBMC layer cells was ana-
lyzed. As expected, Lu/BCAM were not expressed on
PBMC35 (Figure 4C, middle panel). Heterogeneous expres-
sion of Lu/BCAM on RBC within the same individual was
confirmed for all sickle cell disease patients analyzed in
this experiment (Figure 4C, middle panel, typical result).
The patients showed different proportions of Lu/BCAM-
negative and -positive (median: 56.1%, n=5) RBC in the
PBMC layer (Figure 4D). The heterogeneity of Lu/BCAM
distribution found among total RBC was not conserved in
the aggregates as all RBC involved in aggregates stained
positive for Lu/BCAM (median: 95.1%) (Figure 4C, right
panel, 4D). The absence of Lu/BCAM-negative RBC and
the exclusive presence of Lu/BCAM-positive RBC in
aggregates strongly suggested that Lu/BCAM were the
erythroid proteins involved in the PBMC-RBC interaction.
Aggregation rate is lower in patients treated 
with hydroxycarbamide
The effect of hydroxycarbamide treatment on RBC-
PBMC aggregation was investigated. Eight hydroxycar-
bamide-treated patients were analyzed and compared to
17 untreated patients. The median of the aggregation per-
centage was significantly lower for the treated patients
than for the untreated ones (0.68% versus 2.11%, P=0.013)
V. Chaar et al.
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Figure 1. Abnormal SS RBC co-selection during PBMC density gradi-
ent separation. (A)  Typical histograms representing flow cytometry
analysis of the PBMC layer in one AA  subject (left panels) and one
SS patient (right panels). Upper and lower panels represent CD45-
FITC (PBMC) and GPA-PE (RBC) staining, respectively. The horizontal
lines represent areas of positive events; percentages indicate the
proportions of positive events for  each marker. (B) RBC percentage
in the PBMC layer in AA subjects () (n=5) and SS patients ( )
(n=17). Horizontal lines indicate medians. The percentage of RBC in
the PBMC layer  is significantly higher in SS patients than in AA sub-
jects. *P=0.0013, Mann-Whitney test.  
Figure 2. SS patients have abnormally high rates of RBC-PBMC
aggregates. (A) Typical dot plot representation of the PBMC layer
flow cytometry analysis in one AA subject (left  panel) and one SS
patient (right panel). CD45-FITC and GPA-PE antibodies stain PBMC
and RBC, respectively. CD45-FITC and GPA-PE double-stained events
represent potential RBC-PBMC aggregates. (B) Imaging flow cytom-
etry showing dot plots of one SS patient (upper left panel) and one
AA subject (lower left panel), as in (A). Right panels show typical
examples of brightfield and fluorescent images from the area of
double-stained events. Fluorescent images show, from left to right,
CD45-FITC-labeled PBMC, GPA-PE-labeled RBC or RBC-derived
microparticles and CD45-FITC/GPA-PE double-stained events. The
double-stained area was divided into four parts according to the
RBC:PBMC ratio in aggregates: >2:1 (P1), 2:1 (P2), 1:1 (P3). The
fourth part shows the presence of PBMC interacting with RBC-
derived microparticles (P4). Double-stained events from the AA sub-
ject were essentially restricted to PBMC interacting with RBC-derived
microparticles (P5). (C) Percentages of PBMC involved in aggregates
in AA subjects () (n=5) and SS patients ( ) (n = 17). Horizontal
lines indicate medians. *P=0.0048, Mann-Whitney test. 
A
B
C
B
A
AA subject
AA SS
SS patient
CD45-FITCCD45-FITC
GPA-PE
%
 R
BC
s 
in
 P
BM
C 
la
ye
r
Ev
en
ts
Ev
en
ts
Ev
en
ts
Ev
en
ts
0
50
10
0
15
0
20
0
25
0
0
50
10
0
15
0
20
0
25
0
0
50
10
0
15
0
20
0
25
0
0
50
10
0
15
0
20
0
25
0
GPA-PE
AA SS
CD45 FITC
AA subject
AA subject SS patient
SS patient
105
104
103
0
GP
A-
PE
105
104
103
0
GP
A-
PE
105
104
103
0
GP
A-
PE
GP
A-
PE
%
 P
BM
Cs
 in
 a
gg
re
ga
te
s 6
5
4
3
2
1
0
0 103 104 105
CD45 FITC
CD45 FITC CD45 FITC
Double
stained
events
Double
stained
events
0 103 104 105
100
75
50
25
0
(Figure 5), indicating that hydroxycarbamide diminished
the occurrence of aggregation. However, more aggregates
were still detected in blood samples from hydroxycar-
bamide-treated patients than in those from healthy con-
trols (median: 0.68% versus 0.29%, P=0.0186) (Figure 5).
Discussion
Leukocytes are believed to play a critical role in sickle
cell disease by aggregating with RBC and platelets and by
adhering to and stimulating the vascular endothelium.
This stimulation leads to increased expression of RBC
adhesion molecule ligands, thus contributing to vaso-
occlusion.15 In the present study, we revealed the presence
of aggregates involving SS RBC and PBMC in whole blood
from sickle cell disease patients after enrichment of PBMC
by density gradient separation. Previous studies using in
vitro binding assays,28,30 a sickle cell disease mouse model27
and an in vitro flow model of vaso-occlusion29 suggested
interactions between the two cell types in sickle cell dis-
ease.
Because of their size and their multiple potential interac-
tions with the vascular wall, leukocyte-RBC aggregates
could initiate or aggravate vaso-occlusion by disrupting
microcirculatory blood flow. Intravital microscopy studies
in a sickle cell disease mouse model revealed that adherent
leukocytes in inflamed venules played a direct role in
vaso-occlusion by trapping circulating SS RBC.27 Inhibition
of leukocyte-RBC interactions with a high dose of intra-
venous immune globulin prevented venular vaso-occlu-
sion in these mice.36 A novel mechanism that may con-
tribute to vaso-occlusion was described, in which incubat-
ing leukocytes with SS RBC, in particular with epineph-
rine-activated SS RBC, stimulated their adhesion to
endothelial cells in vitro.31 Our imaging flow cytometry
analysis gave strong evidence of the abnormal RBC-PBMC
interactions that could occur in sickle cell disease patients’
whole blood, as circulating leukocyte-RBC aggregates
were visualized for the first time. Based on the study by
Zennadi et al.,31 the presence of such interactions in whole
blood could lead to activation of PBMC and contribute to
abnormal cell adhesion to the vascular wall. The imaging
flow cytometry revealed that a PBMC could interact with
more than one SS RBC in cell aggregates. It also enabled
the visualization of aggregates between PBMC and RBC-
derived microparticles in both sickle cell disease patients
and AA controls. The imaging flow cytometry assay was
essential to determine the composition of the aggregates
and to optimize the gating in the classical flow cytometry
assays that followed, taking into account aggregates com-
prising whole cells and excluding those with RBC-derived
Mononuclear and sickle red blood cell interactions 
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Figure 3. SS RBC and PBMC populations
involved in aggregation. (A) Aggregates
include both mature SS RBC and reticulo-
cytes. Typical results showing cells from the
PBMC layer labeled with FITC-conjugated anti-
CD45, PE-conjugated anti-GPA and APC-con-
jugated anti-CD71 antibodies. The dot plot
representation in the left panel shows gated
events corresponding to SS RBC, PBMC and
aggregates. Each of these three populations
was gated and analyzed for CD71 expression,
as shown in the middle panel. CD71 expres-
sion in aggregates is magnified in the right
panel. The bold horizontal lines represent
CD71-positive events. (B) Monocytes have a
greater ability to aggregate than lympho-
cytes. The dot plot representation in the left
panel is as for (A). Lymphocytes (L) and
monocytes (M) were distinguished among
PBMC and aggregates using morphological
parameters (forward versus side scatter, right
panels). (C) Percentage of lymphocytes ()
and monocytes ( ) in the PBMC population
and in aggregates. Horizontal lines indicate
medians. 
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microparticles.
Our study indicated that both SS reticulocytes and
mature RBC were involved in aggregation with PBMC. In
contrast, Brittain et al. reported that reticulocytes repre-
sented the primary cells interacting with leukocytes.30 Our
results were obtained after specific cell surface labeling of
reticulocytes and showed the presence of both cell types
(reticulocytes and mature RBC) in cell aggregates, whereas
Brittain et al. showed a positive correlation between the
number of GPA+/CD45+ events and reticulocyte count,
which does not exclude the presence of mature RBC in
aggregates. Our finding is supported by the results of a
study by Zennadi et al. in which both SS reticulocytes and
mature RBC were shown to interact with PBMC and
induce their adhesion to endothelial cells in vitro.31
Moreover, in prior studies, dense (mostly mature) SS RBC
were more adherent to polymorphonuclear neutrophil
monolayers than light (mostly young) SS RBC,28 reinforc-
ing our finding concerning the ability of mature SS RBC to
interact with leukocytes.
In our study, SS RBC interacted preferentially with
monocytes within the aggregates, as previously described
in whole blood.30 These interactions could result from the
presence of activated monocytes, as sickle cell disease is
characterized by an inflammatory state reflected by acti-
vation of monocytes37-39 and polymorphonuclear neu-
trophils.40 Although the majority of the PBMC involved in
aggregates were monocytes, 39.33% (median) were lym-
phocytes, indicating the ability of these latter cells to inter-
act with SS RBC. Zennadi et al. reported that SS RBC
induced adhesion of both lymphocytes and monocytes to
endothelial cells,31 suggesting an interaction between SS
RBC and both PBMC types. Our results strongly support
the presence of direct interactions between lymphocytes
and SS RBC in vivo, suggesting that, in addition to neu-
trophils and monocytes, lymphocytes may also contribute
to the pathophysiology of sickle cell disease.
We identified α4β1 integrin and Lu/BCAM as cell surface
proteins involved in RBC-PBMC aggregation. α4β1 integrin
is expressed on leukocytes and reticulocytes whereas
Lu/BCAM expression is specific to the erythroid lineage
among circulating blood cells. The involvement of α4β1 in
RBC-PBMC aggregation was shown by the inhibition
assays using VCAM-1-Fc and anti-β1 blocking antibody.
Inhibition was variable but statistically significant in two
sets of six patients, even though the aggregation was not
totally abolished. This was probably due to the difficulty
of VCAM-1-Fc and anti-β1 antibody to compete with the
established interaction between α4β1 and its erythroid lig-
and. An interaction between reticulocyte α4β1 and
endothelial Lu/BCAM had already been described in sickle
cell disease patients.14 Our current study suggested that
α4β1 on the surface of PBMC could interact with erythroid
Lu/BCAM in the RBC-PBMC aggregates. Plasma
V. Chaar et al.
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Figure 4. α4β1 integrin and Lu/BCAM are
involved in RBC-PBMC aggregation.
Inhibition assays using VCAM-1-Fc (A) or
anti-β1 antibody (B). *P=0.03,
Wilcoxon's  matched-pairs test. (C) The
dot plot representation in the left panel
shows gated events  corresponding to
SS RBC, PBMC and aggregates. Each of
these three populations was gated and
analyzed for Lu/BCAM expression, as
shown in the middle panel. Lu/BCAM
expression in aggregates is magnified
in the right panel. Bold horizontal lines
represent Lu/BCAM-positive events. (D)
Percentage of Lu/BCAM-positive events
in the RBC population ( ) and  in aggre-
gates () of five SS patients. Horizontal
lines indicate medians.  
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fibronectin was found to mediate interactions between
monocytes and SS reticulocytes by bridging α4β1 mole-
cules on both sides in in vitro adhesion assays and in blood
from patients with sickle cell disease.30 Our experiments
showed that both SS reticulocytes and mature RBC,
which do not express α4β1, were involved in aggregates,
suggesting that cell-cell interactions were not dependent
on fibronectin. It has also been shown that epinephrine-
treated SS RBC induce PBMC adhesion to endothelial cells
via at least two erythroid receptors, LW and CD44.31
Nevertheless, the Lu/BCAM-α4β1 interaction seems to be
the primary interaction responsible for the RBC-PBMC
aggregates that we identified, since no Lu/BCAM-negative
RBC were found within these aggregates.
We also investigated the effect of hydroxycarbamide
treatment on RBC-PBMC aggregation. Hydroxycarbamide
therapy is associated with clinical benefits in sickle cell dis-
ease by reducing the frequencies of painful vaso-occlusive
crises and admissions to hospital32 but its mechanism of
action is still poorly understood. We found that the rates of
aggregates were lower in hydroxycarbamide-treated
patients than in untreated patients. A similar observation
was made in a flow model of vaso-occlusion in which
hydroxycarbamide inhibited the interactions between
adherent leukocytes and flowing SS RBC in vitro.29 The
inhibition that we detected was probably not due to a
lower expression of Lu/BCAM on the surface of SS RBC,
as hydroxycarbamide-treatment increases the percentage
of Lu/BCAM-positive SS RBC and the level of Lu/BCAM
expression/RBC.41 It could be due to the inhibition of
Lu/BCAM and/or α4β1 activities as both molecules are
known to be activated by phosphorylation of their cyto-
plasmic domain.6,13 Hydroxycarbamide therapy for sickle
cell disease also targets leukocytes by reducing their num-
ber, decreasing their activation and modulating their
expression of adhesion molecules.42-45 Although hydroxy-
carbamide decreases α4β1 expression on SS reticulo-
cytes,41,46 to our knowledge, the effect of hydroxycar-
bamide-treatment on α4β1 in sickle cell disease leukocytes
has not been investigated yet. A recent study showed that
hydroxycarbamide treatment diminishes the expression
of genes encoding for inflammatory mediators, such as
tumor necrosis factor-α, in sickle cell disease mononuclear
cells.44 Such a decrease in tumor necrosis factor-α could
have a direct inhibitory effect on sickle cell disease
mononuclear cell activation and could thus modulate α4β1
binding activity.47 The decrease of RBC-PBMC aggregation
associated with hydroxycarbamide treatment could
explain, in part, the clinical benefit of hydroxycarbamide
therapy: more investigations are necessary to confirm this
hypothesis.
In conclusion, our study provided visual evidence of the
existence of RBC-PBMC aggregates in patients with sickle
cell disease and showed that the aggregation rate is
decreased during hydroxycarbamide treatment. Our
results strongly suggest that erythroid Lu/BCAM are
involved in this aggregation through their interaction with
α4β1 integrin on PBMC. Future investigations should help
to characterize the mechanisms leading to this interaction
and evaluate the impact of aggregates on the occurrence of
vaso-occlusive crises, which could generate new therapeu-
tic perspectives.
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